Use of quality indicators to evaluate the care of patients with localized prostate carcinoma
dc.contributor.author | Miller, David C. | en_US |
dc.contributor.author | Litwin, Mark S. | en_US |
dc.contributor.author | Sanda, Martin G. | en_US |
dc.contributor.author | Montie, James E. | en_US |
dc.contributor.author | Dunn, Rodney L. | en_US |
dc.contributor.author | Resh, Jennifer | en_US |
dc.contributor.author | Sandler, Howard M. | en_US |
dc.contributor.author | Wei, John T. | en_US |
dc.date.accessioned | 2006-04-19T13:31:04Z | |
dc.date.available | 2006-04-19T13:31:04Z | |
dc.date.issued | 2003-03-15 | en_US |
dc.identifier.citation | Miller, David C.; Litwin, Mark S.; Sanda, Martin G.; Montie, James E.; Dunn, Rodney L.; Resh, Jennifer; Sandler, Howard; Wei, John T. (2003)."Use of quality indicators to evaluate the care of patients with localized prostate carcinoma." Cancer 97(6): 1428-1435. <http://hdl.handle.net/2027.42/34367> | en_US |
dc.identifier.issn | 0008-543X | en_US |
dc.identifier.issn | 1097-0142 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/34367 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=12627506&dopt=citation | en_US |
dc.description.abstract | BACKGROUND The goal of quality assurance in health care is to preserve and improve patient care. Recently, RAND developed a set of evidence-based candidate indicators for evaluating the quality of care for patients with localized prostate carcinoma; however, the feasibility and sensitivity of these indicators have not been tested in a clinical setting. The objectives of this study were to evaluate the feasibility of measuring these quality indicators and to determine their sensitivity to change in practice patterns over time. METHODS One hundred sixty-eight men who presented in either 1995 or in 2000 and were treated for localized prostate carcinoma were selected randomly from the University of Michigan tumor registry. A combination of electronic data base review and explicit chart review was used to assess the feasibility of measuring compliance for each indicator. For each indicator in which assessment was feasible, compliance with the RAND indicators was determined for patients in both years. Multivariate regression analysis was used to adjust for potential confounding effects of disease stage, tumor grade, prostate specific antigen (PSA) level, patient age, and therapy. RESULTS Based on review of available clinical data, measurement of compliance was feasible for 19 of 22 RAND candidate quality indicators (86%). For five indicators, significant differences in documentation (compliance) were detected between 1995 and 2000 ( P < 0.05). Treatment received and higher PSA levels were associated independently with documentation of compliance for several indicators ( P < 0.05). CONCLUSIONS Measurement of the majority of the RAND quality indicators for the treatment of patients with localized prostate carcinoma was feasible, and improvements in several indicators were observed between 1995 and 2000. Demonstration of such variation, even within a single institution, suggests that the indicators are sufficiently sensitive to detect differences in practice patterns. Cancer 2003;97:1428–35. © 2003 American Cancer Society. DOI 10.1002/cncr.11216 | en_US |
dc.format.extent | 129748 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Cancer Research, Oncology and Pathology | en_US |
dc.title | Use of quality indicators to evaluate the care of patients with localized prostate carcinoma | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Urology, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Urology, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Urology, University of Michigan, Ann Arbor, Michigan ; James E. Montie is an investigator for Astra Zeneca and UroCor. | en_US |
dc.contributor.affiliationum | Department of Urology, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Urology, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Urology, University of Michigan, Ann Arbor, Michigan ; The Veterans Affairs Center for Practice Management and Outcomes Research, Ann Arbor Veterans Affairs Medical Center, Ann Arbor, Michigan ; Fax: (734) 936-9127 ; Department of Urology, Taubman Health Care Center, University of Michigan Health System, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0330 | en_US |
dc.contributor.affiliationother | Departments of Urology and Health Services, University of California-Los Angeles, Los Angeles, California | en_US |
dc.identifier.pmid | 12627506 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/34367/1/11216_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1002/cncr.11216 | en_US |
dc.identifier.source | Cancer | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.